title: Idarucizumab: The Antidote for Reversal of Dabigatran.
authors.affiliation: From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.).
authors.forename: John W
authors.initials: JW
authors.lastname: Eikelboom
authors.affiliation: From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.). dan.quinlan@nhs.net.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Quinlan
authors.affiliation: From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.).
authors.forename: Joanne
authors.initials: J
authors.lastname: van Ryn
authors.affiliation: From Departments of Medicine (J.W.E., J.I.W.) and Biochemistry and Biomedical Sciences (J.I.W.), McMaster University, Hamilton, ON, Canada; Thrombosis and Atherosclerosis Research Institute, Hamilton, ON, Canada (J.W.E., J.I.W.); Department of Radiology, King's College Hospital, London, UK (D.J.Q.); and CardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany (J.v.R.).
authors.forename: Jeffrey I
authors.initials: JI
authors.lastname: Weitz
mesh_terms: D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000931:Antidotes / Q000627:therapeutic use*; D000991:Antithrombins / Q000009:adverse effects; D017321:Clinical Trials, Phase I as Topic; D000069604:Dabigatran / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy*; D006801:Humans; D017434:Protein Structure, Tertiary
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000931:Antidotes; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran
keywords: anticoagulant; dabigatran; hemorrhage; idarucizumab